What question did this study set out to answer?

To evaluate the safety, synchronization potential, and antitumor efficacy of continuous intravenous bleomycin infusion followed by sequential antimetabolite therapy in patients with advanced metastatic malignancies.

October 1, 1976CancerOpen Access

Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies.A preliminary report

View Full Paper

Ask AI

Bookmark

Authors

JCJohn J. CostanziRoswell Park Comprehensive Cancer Center DLDemetrius F. LoukasTexas Oncology RGRobert G. GaglianoDignity Health

Discussion

Member takes

Implication

Clinical trial reveals antitumor activity of bleomycin infusion followed by antimetabolites in advanced carcinomas, suggesting potential efficacy via cell cycle synchronization.

Key Points

To evaluate the safety, synchronization potential, and antitumor efficacy of continuous intravenous bleomycin infusion followed by sequential antimetabolite therapy in patients with advanced metastatic malignancies.
Administered a 48-hour continuous intravenous bleomycin infusion followed by a 24-hour rest period and a single dose of either methotrexate or hydroxyurea to 36 adult patients with disseminated carcinoma.
Assessed tumor response rates, response durations, and adverse toxicity events across multiple cancer types, adjusting dose intervals following observed hematologic toxicity.
Objective tumor regression occurred in 59% of patients with epidermoid carcinoma of the head and neck, 4 of 4 patients with transitional cell bladder carcinoma, and 1 patient with hypernephroma, with 0 responses among 5 patients with epidermoid lung carcinoma.
The duration of response ranged from 1 to 8 months with a median duration of 2 months, occurring in a cohort where 77% of responders had received prior extensive radiation therapy.
Adverse effects included an initial fatal case of neutropenic sepsis, after which treatment intervals were lengthened, resulting in subsequent toxicities that were predominantly mild or reversible neutropenia.

Cite This Study

Costanzi et al. (1976) studied this question.

synapsesocial.com/papers/6a7148725d37378ac1de70d2 https://doi.org/10.1002/1097-0142(197610)38:4<1503::aid-cncr2820380410>3.0.co;2-9

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial reveals antitumor activity of bleomycin infusion followed by antimetabolites in advanced carcinomas, suggesting potential efficacy via cell cycle synchronization.

Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies.A preliminary report

Discussion

Member takes

Implication

Key Points

Cite This Study

Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies.A preliminary report

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider